Proteins

Product Data Sheet

(E)-3,4,5-Trimethoxycinnamic acid

Cat. No.: HY-W050162 CAS No.: 20329-98-0 Molecular Formula: $C_{12}H_{14}O_{5}$ 238.24 Molecular Weight:

Target: GABA Receptor; 5-HT Receptor

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling; GPCR/G Protein

-20°C Storage: Powder 3 years

> 4°C 2 years In solvent -80°C 6 months -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (419.74 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.1974 mL	20.9872 mL	41.9745 mL
	5 mM	0.8395 mL	4.1974 mL	8.3949 mL
	10 mM	0.4197 mL	2.0987 mL	4.1974 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution

BIOLOGICAL ACTIVITY

Description (E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-

Trimethoxycinnamic acid is an orally active and potent GABA_A/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT_{2C} and 5-HT_{1A} receptor, with IC₅₀ values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the

research of insomnia, headache and epilepsy^{[1][2][3]}.

In Vitro (E)-3,4,5-Trimethoxycinnamic acid (10 μg/mL, 1 h) increases the expressions of GAD₆₅ and γ-subunit of GABA_A receptors in

	namic acid (0-10 μ g/mL, 1 h) shows a significant increase in Cl $^-$ influx ^[3] . ntly confirmed the accuracy of these methods. They are for reference only.	
Cell Line:	Primary cultured cerebellar granule cells	
Concentration:	10 μg/mL	
Incubation Time:	1h	
Result:	Increased expression of GAD ₆₅ (glutamic acid decarboxylase) and γ-subunit of GABAA receptors, but did not influence the amounts of a-, b-subunits in the GABAA receptors.	
Cell Viability Assay ^[3]		
Cell Line:	Primary cultured cerebellar granule cells	
Concentration:	1, 3, 5, 10 μg/mL	
Incubation Time:	1h	
Result:	Produced a significant increase in Cl ⁻ influx.	

In Vivo

(E)-3,4,5-Trimethoxycinnamic acid (0-20 mg/kg, IP, once) shows anti-seizure effects $^{\rm [2]}$.


(E)-3,4,5-Trimethoxycinnamic acid (0-10 mg/kg, Orally, once) enhances hypnotic effects in pentobarbital-treated mice^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ault male KunMing-strain mice (18-20 g, maximal electroshock (MES) and pentylenetetrazol (PTZ) models) $^{\rm [2]}$		
Dosage:	5, 10 and 20 mg/kg; 10 mL/kg		
Administration:	IP, once		
Result:	Significantly decreased the incidence of MES-induced THE (tonic hindlimb extension) to 50% and 20% of the value of the vehicle controls at 10 and 20 mg/kg. Decreased the incidence of MES-induced THE to only 80% at 5 mg/kg. Significantly delayed the onset of myoclonic jerks (MJ), and decreased the seizure severity and mortality compared with the vehicle-treated animals in PTZ seizure model. The incidence of generalized clonic convulsions (stage 4) disappeared at doses of both 10 and 20 mg/kg.		
Animal Model:	ICR male mice (25-28 g, 10-12 in each group) ^[3]		
Dosage:	2,5 and 10 mg/kg		
Administration:	Orally (p.o.), once, 15 min and 1 h prior to pentobarbital injection		
Result:	Significantly decreased locomotor activity at 10 mg/kg. Increased NREM and total sleep, but decreased wakefulness.		

REFERENCES

[1]. Zhao Z, et al. Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. Eur J Med Chem. 2019 Jul 1;173:213-227.

Page 2 of 3 www.MedChemExpress.com



Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com